A Phase II Open-Label Multicenter Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as neoadjuvant and adjuvant therapy in Patients with Stage IB II or IIIA resectable and untreated non-small cell lung cancer

Brief description of study

The main goal of this phase II study is to evaluate the effectiveness of atezolizumab (a monoclonal antibody against Programmed cell death-ligand (PD-L1)) in early-stage non-small cell lung cancer prior to definitive surgery.


Clinical Study Identifier: s16-02095
ClinicalTrials.gov Identifier: NCT02927301
Principal Investigator: Elaine Shum
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.